Home » Stocks » ORIC

Oric Pharmaceuticals Inc. (ORIC)

Stock Price: $17.21 USD -0.68 (-3.80%)
Updated Jul 29, 2021 4:00 PM EDT - Market closed
After-hours: $17.25 +0.04 (0.23%) Jul 29, 5:50 PM
Market Cap 702.96M
Revenue (ttm) n/a
Net Income (ttm) -81.34M
Shares Out 36.68M
EPS (ttm) -2.66
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 29
Last Price $17.21
Previous Close $17.89
Change ($) -0.68
Change (%) -3.80%
Day's Open 17.95
Day's Range 17.16 - 18.20
Day's Volume 71,124
52-Week Range 15.97 - 40.81

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Oric Pharmaceuticals Inc (NASDAQ: ORIC) has announced initial data from an ongoing Phase 1b study evaluating ORIC-101 in combination with nab-paclitaxel, in advanced solid tumors. Data will be presented...

1 month ago - Benzinga

Initial safety data showed combination regimen at the recommended Phase 2 dose was well tolerated; treatment-related adverse events primarily Grade 1 or 2, with no treatment-related discontinuations

1 month ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 26, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mec...

2 months ago - GlobeNewsWire

Lead program ORIC-101 on track for two initial Phase 1b data readouts in 2021

2 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 28, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address m...

3 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO and SAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanism...

3 months ago - GlobeNewsWire

Lead program ORIC-101 on track for two initial data readouts in 2021

4 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 10, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address m...

4 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 02, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address m...

4 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb. 03, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address me...

5 months ago - GlobeNewsWire

Lead program ORIC-101 continues patient enrollment investigating two therapeutic mechanisms of action and on track for two initial data readouts in 2021

6 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 04, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address me...

6 months ago - GlobeNewsWire

Initiated Part II expansion of the Phase 1b study of ORIC-101 in combination with Abraxane (nab-paclitaxel) using recommended Phase 2 dose selected from Part I of the study

7 months ago - GlobeNewsWire

ORIC Pharmaceuticals (ORIC) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

7 months ago - Zacks Investment Research

About ORIC

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. The company's lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. Its other product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-9... [Read more...]

Industry
Biotechnology
IPO Date
Apr 24, 2020
CEO
Jacob Chacko
Employees
66
Stock Exchange
NASDAQ
Ticker Symbol
ORIC
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for ORIC stock is "Strong Buy." The 12-month stock price forecast is 43.14, which is an increase of 150.67% from the latest price.

Price Target
$43.14
(150.67% upside)
Analyst Consensus: Strong Buy